Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Study of GBR 1342, a CD38 / CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma

Multiple Myeloma

The purpose of this study is to determine the safety profile and maximum tolerable dose (MTD) of single-agent GBR 1342 in subjects with multiple myeloma who have received prior therapies.
Multiple Myeloma
I
Cornell, Robert
NCT03309111
VICCHEMP17111

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: